Drugs / N-desmethylclobazam
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03375034 | Mar → Dec 2017 | neuropathy, painful | Jules Desmeules | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04480164 | Jun 2020 → Sep 2022 | neuropathy, painful | Besson Marie | Suspended | No outcome recorded Stop: Enrollment |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT01713946 Background | Apr 2013 → Oct 2017 | tuberous sclerosis | Novartis Pharmaceuticals | Completed | Met primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | N-desmethylclobazam | “N-Desmethylclobazam (NDMC), clobazam's main active metabolite, demonstrated in vitro and in vivo a high selectivity profile with a clear preference for GABAA α2-subtypes...” NCT04480164 ↗2“List of allowed antiepileptic drugs were: valporic acid, carbamazepine, clobazam, N-desmethylclobazam, topiramate,TRI477, TRI476, clonazepam, zonisamide, phenobarbital, phenytoin” NCT01713946 ↗ “GABAA Agonist N-desmethylclobazam” NCT03375034 ↗ |
| Known as | NDMC | “N-Desmethylclobazam (NDMC), clobazam's main active metabolite, demonstrated in vitro and in vivo a high selectivity profile with a clear preference for GABAA α2-subtypes...” NCT04480164 ↗1“α1-sparing selective benzodiazepines, such as N-desmethylclobazam (NDMC)” NCT03375034 ↗ |
| Action | Activate | “GABAA Agonist N-desmethylclobazam” NCT03375034 ↗ |
| Modality | Small molecule | “α1-sparing selective benzodiazepines, such as N-desmethylclobazam (NDMC)” NCT03375034 ↗ |
| Route | Oral | “Oral administration of one NDMC 20mg capsule and two Placebo capsules” NCT03375034 ↗ |